Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

Stopped Protocol changed to use subcutaneous rather than intravenous daratumumab.

Conditions

• Allosensitization
• Heart Transplant Failure and Rejection

Interventions

• DRUG: Daratumumab

Sponsor

Ronald Witteles